The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: A retrospective long-term follow-up analysis of a regional Italian experience

Annals of Hematology

Volumn 88, Issue 9, 2009, Pages 855-861

  Olcese, Francesca ^a   Clavio, Marino ^a   Rossi, Edoardo ^a   Spriano, Mauro ^a   Ballerini, Filippo ^a   Canepa, Letizia ^a   Pierri, Ivana ^a   Aquino, Sara ^a   Varaldo, Riccardo ^a   Manna, Annunziata ^b   Secondo, Vincenzo ^c   Racchi, Omar ^d   Balleari, Enrico ^a   Orcioni, Giulio Fraternali ^a   Carella, Angelo Michele ^a   Ghio, Riccardo ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b La Spezia Hospital   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d VILLA SCASSI HOSPITAL   (Italy)

Author keywords

ABVD; Early stage; Hodgkin's lymphoma; Late toxicity; Radiotherapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INJURY; RETROSPECTIVE STUDY; REVIEW; SECOND CANCER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67849094261     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0699-5     Document Type: Review

References (26)

1. Diehl V (2007) Hodgkin's disease, from pathology specimen to cure. N Engl J Med 357:1968-1971
2. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514
3. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
4. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614
5. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Intergruppo Italiano Linfomi et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207
6. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. Standard and increased-dose BEACOPP. N Eng J Med 348:2386-2395
7. Diehl V, Fuchs M (2007) Early, intermediate and advanced Hodgkin's lymphoma: Modern treatment strategies. Ann Oncol 18(Suppl 9):71-79
8. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol. 22:2835-2841
9. Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO et al (2006) Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: Cure balanced against complications. J Clin Oncol 24:605-611
10. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol. 25:3495-3502
11. Fermè C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. EORTC-GELA H8 Trial. N Engl J Med 357:1916-1927
12. Olweny CL, Ziegler JL (2008) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 358:742-759
13. Hoppe RT (1997) Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115-118
14. Ghalibafian M, Beaudre A, Girinsky T (2008) Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk. Radiother Oncol 87:82-88
15. Travis LB (2007) Evaluation of the risk of therapy-associated complications in survivors of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007:192-196
16. Kwong A, Hancock SL, Bloom JR, Pal S, Birdwell RL, Mariscal C et al (2008) Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin's disease. Breast J 14:39-48
17. Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M et al (2007) Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 110:2576-2586
18. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK Pai SK et al (2004) Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need. J Clin Oncol 22:62-68
19. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C et al (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483-3489
20. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642
21. Gospodarowicz MK, Meyer RM (2006) The management of patients with limited-stage classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:253-258
22. Jaffe ES, Lee Harris N, Stein H, Vardiman JW (2001) World Health Organization Classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC, Lyon
23. Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A et al (2008) German Hodgkin Study Group. Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-439
24. Eich HT, Müller RP (2007) Current role and future developments of radiotherapy in early-stage favourable Hodgkin's lymphoma. Strahlenther Onkol 183:16-18
25. Hoppe RT (2007) Hodgkin's lymphoma: The role of radiation in the modern combined strategies of treatment. Hematol Oncol Clin North Am 21:915-927
26. Macdonald DA, Connors JM (2007) New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am 21:871-880